Michael Gelband’s Madrigal Pharmaceuticals MDGL Stock Holding History

Michael Gelband’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.82M	Sell	3,384 -2,186	-39%	-$1.12M	0.01%	859
2026 Q1	$2.92M	Buy	+5,570	New	+$2.66M	0.02%	629
2025 Q3	–	Sell	-2,878	Closed	-$871K	–	1830
2025 Q2	$871K	Buy	+2,878	New	+$857K	0.01%	1000
2024 Q4	–	Sell	-2,645	Closed	-$561K	–	1830
2024 Q3	$561K	Buy	+2,645	New	+$677K	﹤0.01%	1151
2023 Q4	–	Sell	-8,162	Closed	-$1.19M	–	1819
2023 Q3	$1.19M	Buy	+8,162	New	+$1.54M	0.01%	902
2023 Q2	–	Sell	-1,060	Closed	-$257K	–	2095
2023 Q1	$257K	Buy	+1,060	New	+$289K	﹤0.01%	1510
2022 Q4	–	Sell	-9,177	Closed	-$596K	–	1926
2022 Q3	$596K	Buy	9,177 +5,388	+142%	+$374K	0.01%	1302
2022 Q2	$271K	Buy	+3,789	New	+$279K	﹤0.01%	1568
2020 Q4	–	Sell	-2,089	Closed	-$248K	–	2208
2020 Q3	$248K	Buy	+2,089	New	+$227K	﹤0.01%	1375

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's MDGL Position: Q2 2026 in Review

Michael Gelband reduced its Madrigal Pharmaceuticals (MDGL) stake by 39% in Q2 2026, selling an estimated $1.12M and leaving 3,384 shares worth $1.82M. The position accounts for 0.01% of the portfolio, ranked #859.

Michael Gelband first reported a position in MDGL in Q3 2020 and has held it in 9 quarters since. The position peaked at $2.92M in Q1 2026. 411 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Michael Gelband held 3,384 shares of Madrigal Pharmaceuticals worth $1.82M as of Q2 2026.
Michael Gelband sold 2,186 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $1.12M.
Madrigal Pharmaceuticals made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #859 holding.
Michael Gelband first reported a position in Madrigal Pharmaceuticals in Q3 2020 and has held it in 9 quarters since.
Michael Gelband's Madrigal Pharmaceuticals position peaked at $2.92M in Q1 2026.
411 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.